Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03228420
Other study ID # CA2016-5
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date July 20, 2017
Est. completion date December 1, 2022

Study information

Verified date July 2021
Source Nevro Corp
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This post-market study is being conducted to document comparative safety, clinical effectiveness, and cost-effectiveness of the addition of HF10™ therapy to CMM compared with CMM alone in subjects with chronic, intractable, neuropathic lower limb pain due to diabetic neuropathy (Painful Diabetic Neuropathy or PDN). This study is a multi-center, prospective, randomized comparison of the two treatments.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 430
Est. completion date December 1, 2022
Est. primary completion date May 1, 2020
Accepts healthy volunteers No
Gender All
Age group 22 Years and older
Eligibility Inclusion Criteria: 1. Have been clinically diagnosed with painful diabetic neuropathy (PDN) of the lower limbs. 2. Average pain intensity of = 5 out of 10 cm on the VAS in the lower extremities at enrollment. 3. Have stable neurological status. 4. Be on a stable analgesic regimen. 5. Be 22 years of age or older at the time of enrollment. 6. Be an appropriate candidate for the surgical procedures required in this study. 7. Be capable of subjective evaluation, able to read and understand English-written questionnaires, and able to read, understand and sign the written informed consent in English. 8. Be willing and capable of giving informed consent. 9. Be willing and able to comply with study-related requirements, procedures, and scheduled visits. Exclusion Criteria: 1. Have a diagnosis of a lower limb mononeuropathy, have had a lower limb amputation, or have large (=3 cm) and/or gangrenous ulcers of the lower limbs. 2. Have a BMI = 40. 3. Currently prescribed a daily opioid dosage > 120 mg morphine equivalents. 4. Have a medical condition or pain in other area(s), not intended to be treated in this study. 5. Have a current diagnosis of a progressive neurological disease such a multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, rapidly progressive arachnoiditis, brain or spinal cord tumor, central deafferentation syndrome, Complex Regional Pain Syndrome, acute herniating disc, severe spinal stenosis and brachial plexus injury. 6. Have a current diagnosis or condition such as a coagulation disorder, bleeding diathesis, platelet dysfunction, low platelet count, severely diminished functional capacity due to underlying cardiac/pulmonary disease, symptomatic uncontrolled hypertension, progressive peripheral vascular disease or uncontrolled diabetes mellitus that presents excess risk for performing the procedure. 7. Have failed prior SCS, dorsal root ganglion (DRG) stimulation, or peripheral nerve stimulation (PNS) trials for chronic intractable pain. 8. Have significant spinal stenosis, objective evidence of epidural scarring and/or any signs or symptoms of myelopathy. 9. Any previous history of surgery on the posterior elements (laminectomy, posterior fusion) resulting in a compromised epidural space. 10. Be benefitting from an interventional procedure and/or surgery to treat lower limb pain. 11. Have an existing drug pump and/or another active implantable device such as a pacemaker. 12. Have a condition currently requiring or likely to require the use of diathermy or MRI that is inconsistent with Senza system guidelines in the Physician's Manual. 13. Have either a metastatic malignant neoplasm or untreated local malignant neoplasm. 14. Have a life expectancy of less than one year. 15. Have a local infection at the anticipated surgical entry site or an active systemic infection. 16. Be pregnant or plan to become pregnant during the study. Women of childbearing potential who are sexually active must use a reliable form of birth control, be surgically sterile, or be at least 2 years post-menopausal. 17. Have within 6 months of enrollment a significant untreated addiction to dependency producing medications, alcohol or illicit drugs. 18. Be concomitantly participating in another clinical study. 19. Be involved in an injury claim under current litigation. 20. Be a recipient of Social Security Disability Insurance (SSDI). 21. Have a pending or approved worker's compensation claim. 22. Have evidence of an active disruptive psychological or psychiatric disorder or other known condition significant enough to impact perception of pain, compliance with intervention and/or ability to evaluate treatment outcome.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Senza HF10 Therapy
Senza 10kHz Spinal Cord Stimulation
Other:
CMM
Conventional Medical Management

Locations

Country Name City State
United States Coastal Orthopedics Bradenton Florida
United States Duke University Medical Center Durham North Carolina
United States Advanced Pain Management Greenfield Wisconsin
United States Georgia Pain Care Stockbridge Georgia

Sponsors (1)

Lead Sponsor Collaborator
Nevro Corp

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Composite of Safety and Effectiveness Difference between treatment groups in responder rates in subjects without a clinically meaningful neurological deficit compared with baseline. Responder is defined as a subject who has at least 50% reduction in lower limb pain from Baseline as measured by a 10 cm Visual Analog Scale (VAS). 3 months
Secondary Pain Scores of 3 or Less Difference between the treatment groups in proportion of subjects with a lower limb pain VAS score = 3 cm. 3 months
Secondary Crossover Rates Difference between the treatment groups in crossover rates. Subjects who meet pre-specified criteria may elect to crossover to the other treatment arm at 6-month follow-up. 6 months
Secondary Responder Rates Difference between the treatment groups in responder rates. Responder is defined as a subject who has at least 50% reduction in lower limb pain from Baseline as measured by a 10 cm Visual Analog Scale (VAS). 6 months
Secondary Remitter Rates Difference between the treatment groups in the proportion of remitters (remission is defined as having a lower limb pain VAS score of = 3.0 cm for at least 6 months). 6 months
Secondary Neurological Assessment Difference between the treatment groups in the proportion of subjects with overall improvement from baseline in neurological assessment (motor, sensory, reflex). 3 months
Secondary Neurological Assessment Difference between the treatment groups in the proportion of subjects with overall improvement from baseline in neurological assessment (motor, sensory, reflex). 6 months
Secondary Health-related Quality of Life Difference between the treatment groups in changes in health-related quality of life as assessed by the EuroQol Five Dimensions questionnaire (EQ-5D-5L). 6 months
Secondary Hemoglobin A1c Difference between the treatment groups in the average percentage change from baseline in HbA1c levels. 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT04699734 - Peripheral Nerve Block in Patients With Painful Diabetic Polyneuropathy N/A
Recruiting NCT05480228 - EPPIC-Net: Novaremed Painful Diabetic Peripheral Neuropathy ISA Phase 2
Recruiting NCT05476276 - EPPIC-Net: Platform Protocol to Assess Treatments for Painful Diabetic Peripheral Neuropathy Phase 2
Unknown status NCT01125215 - Capsaicin Nanoparticle in Patient With Painful Diabetic Neuropathy Phase 2/Phase 3
Not yet recruiting NCT05937984 - Treatment for Painful Diabetic Neuropathy N/A
Recruiting NCT05080530 - Vitamin D and Painful Diabetic Neuropathy N/A
Completed NCT04005287 - A 24-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Peripheral Neuropathy Phase 2
Recruiting NCT03331614 - An Evaluation of an SCCD on the Symptomatology of Painful DPN N/A
Recruiting NCT03700528 - The Development of Contextual Cognitive Behavioural Approach to PDN N/A
Recruiting NCT04689958 - The Benefits of Vitamin D 5000 IU as Add on Therapy in the Management of Painful Diabetic Neuropathy Patient Phase 2/Phase 3
Recruiting NCT04689971 - The Benefits of Vitamin B Combination as Add on Therapy in the Management of Painful Diabetic Neuropathy Patient Phase 2/Phase 3
Recruiting NCT04689984 - The Benefits of Astaxanthin as Add on Therapy in the Management of Painful Diabetic Neuropathy Patient Phase 2/Phase 3
Completed NCT03749642 - Trazodone/Gabapentin Fixed Dose Combination Products in Painful Diabetic Neuropathy Phase 2
Not yet recruiting NCT04087941 - Efficacy and Safety of VM202 in Painful Diabetic Peripheral Neuropathy -The HOPES Trial Phase 2
Terminated NCT01129960 - Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain Phase 3
Terminated NCT01056315 - A Trial in Painful Diabetic Peripheral Neuropathy With GRT3983Y Phase 2
Completed NCT00980746 - Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Painful Diabetic Neuropathy Phase 2
Completed NCT04786340 - A 12-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Painful Peripheral Neuropathy Phase 2
Completed NCT03769675 - Quantitative Assessment of Painful Diabetic Peripheral Neuropathy After High Frequency Spinal Cord Stimulation N/A
Completed NCT03755934 - Efficacy and Safety of MEDI7352 in Subjects With Painful Diabetic Neuropathy Phase 2